4 Articles
4 Articles
Hyundai Bioscience is pursuing the development of a treatment for Severe Fever with Thrombocytopenia Syndrome (SFTS), also known as "killer tick disease." The goal is to initiate Phase 2 clinical trials and begin administering the drug to patients around May of next year. On the 13th, at the Korea Press Center in Gwanghwamun, Seoul, Hyundai Bioscience [held] the 'Jefty SFTS Clinical Development Pre-
(Seoul = Yonhap News) Reporter Park Sang-hyun = Hyundai Bioscience is pursuing the development of a treatment for Severe Fever with Thrombocytopenia Syndrome (SFTS), for which there are currently no approved drugs.
Hyundai Bioscience CEO Bae Byoung-jun speaks during a press conference about the anti-viral drug XAFTY in Seoul on Oct. 13. South Korea’s Hyundai Bioscience announced on Oct. 13 that it plans to accelerate the development of a treatment for severe fever with thrombocytopenia syndrome (SFTS). It is a potentially fatal tick-borne infectious disease for which no approved treatment is currently available, according to Hyundai Bioscience. The biophar…
Coverage Details
Bias Distribution
- 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
